Table 1.
Women’s risk of VIA abnormality, given age, concurrent cytology and HPV test results and VIA provider.
| Total | VIA Result (row %) | P-value | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Column % | SCJ Not visible | Suspicious Cancer | Positive | Negative | ||||||
| N | % | N | % | N | % | N | % | ||||
| TOTAL | 1163 | 100.0 | 142 | 12.2 | 80 | 6.9 | 81 | 7.0 | 860 | 74.0 | |
|
| |||||||||||
| Age | |||||||||||
| 15–29 | 238 | 20.5 | 0 | 0.0 | 23 | 9.6 | 18 | 7.6 | 197 | 82.8 | |
| 30–49 | 422 | 36.3 | 9 | 2.1 | 27 | 6.4 | 28 | 6.6 | 358 | 84.8 | |
| 50–95 | 503 | 43.3 | 133 | 26.4 | 30 | 6.0 | 35 | 7.0 | 305 | 60.6 | .56a |
| Cytology | |||||||||||
| Normal | 1037 | 90.2 | 132 | 12.7 | 64 | 6.2 | 69 | 6.7 | 772 | 74.5 | |
| ASCUS/LSIL | 80 | 7.0 | 4 | 5.0 | 10 | 12.5 | 4 | 5.0 | 62 | 77.5 | |
| HSIL/Cancer | 33 | 2.9 | 5 | 15.2 | 2 | 6.1 | 8 | 24.2 | 18 | 54.6 | .008a |
| Oncogenic HPV Status | |||||||||||
| Negative | 977 | 15.9 | 117 | 12.0 | 64 | 6.6 | 63 | 6.5 | 733 | 75.0 | |
| Positive | 184 | 84.1 | 25 | 13.6 | 16 | 8.7 | 18 | 9.8 | 125 | 67.9 | .036b |
| Health Worker | |||||||||||
| A | 212 | 18.3 | 43 | 20.3 | 26 | 12.3 | 11 | 5.2 | 132 | 62.3 | |
| B | 207 | 17.9 | 47 | 22.7 | 18 | 8.7 | 24 | 11.6 | 118 | 57.0 | |
| C | 191 | 16.5 | 2 | 1.1 | 14 | 7.3 | 17 | 8.9 | 158 | 82.7 | |
| D | 99 | 8.6 | 12 | 12.1 | 7 | 7.1 | 4 | 4.0 | 76 | 76.8 | |
| E | 237 | 20.5 | 14 | 5.9 | 14 | 5.9 | 11 | 4.6 | 198 | 83.5 | |
| F | 75 | 6.5 | 21 | 28.0 | 0 | 0 | 4 | 5.3 | 50 | 66.7 | |
| G | 136 | 11.8 | 3 | 2.2 | 1 | 0.7 | 9 | 6.6 | 123 | 90.4 | .001b |
a
Anova p-value. For tests of significance, VIA results of positive and suspicious cancer are combined and excludes women with “SCJ not visible.”
b
Chi-square p-value. For tests of significance, VIA results of positive and suspicious cancer are combined and excludes women with “SCJ not visible.”